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Continuing Education Disclaimer
CDC, our planners, presenters, and their spouses/partners wish to 
disclose they have no financial interests or other relationships with 
the manufacturers of commercial products, suppliers of commercial 
services, or commercial supporters, with the exception of Dr. Mark 
Sullivan and Dr. Joseph Merrill. They would like to disclose that their 
employer, the University of Washington, received a contract payment 
from the Centers for Disease Control and Prevention. 
Planners have reviewed content to ensure there is no bias. 
This presentation will include discussion of the unlabeled use of a 
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Objectives
At the conclusion of this session, the participant will 
be able to:
 Describe all available Food and Drug Administration 
Emergency Use Authorizations for Zika virus assays.
 Discuss Zika virus testing methods, including molecular and 
antibody detection.
 Explain the role of public health laboratories, clinicians, and 
health departments in Zika testing and diagnosis.
 Identify Zika virus laboratory testing algorithms and resources.
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What is new?
CDC updated its laboratory guidance to support improved detection of Zika 
virus infection
Questions: 
• Why has whole blood been added as an approved specimen type for 
detection of Zika virus?  
• Should health care providers still collect serum? 
Updated Guidance for US Laboratories Testing for Zika Virus
• Issued November 16, 2016
• Expands laboratory testing parameters
• Addresses use of currently available commercial assays
• Clarification for testing algorithms
http://www.cdc.gov/zika/laboratories/lab-
guidance.html
Detecting Zika Virus Infection
Zika Diagnostic Assays
• Detection of Zika virus RNA is performed using Nucleic Acid Tests (NATs).
• Zika MAC-ELISA is used for the detection of Zika IgM antibodies.
• Cross-reaction with related flaviviruses (e.g., dengue) is common.
• Specimens tested with the Zika MAC-ELISA that are presumptive positive, 
equivocal or uninterpretable are further analyzed using plaque reduction 
neutralization tests (PRNT).
• PRNT confirmation is not currently routinely recommended in Puerto 
Rico.
CDC Zika Diagnostic Assays
• FDA has issued Emergency Use Authorizations (EUAs) for two CDC 
assays
• Zika MAC-ELISA for presumptive detection of Zika IgM antibodies
• Specimens positive for Zika MAC-ELISA are further analyzed by 
using PRNT.
• Trioplex rRT-PCR to detect Zika, dengue, and chikungunya viral RNA
• CDC Zika diagnostic assays are distributed in the United States through 
the Laboratory Response Network (LRN).
• CDC Zika diagnostic assays have also been distributed internationally.
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika
CDC EUA Updates
 Trioplex rRT-PCR, September 21, 2016
Addition of:
• Whole blood as a specimen type 
• Two new extraction instruments
– MagNA Pure Compact
– BioMerieux easyMAG
• Large volume (1 mL) extraction preferred for serum, urine, CSF, 
and amniotic fluid (using authorized instrumentation)
 Patient and healthcare provider fact sheets updated
Additional Capacity for Zika Diagnostic Testing
• Ten commercial diagnostic manufacturers have received an EUA for a 
molecular test for Zika virus RNA.
• FDA reference panel sent to all manufacturers for blind testing and test performance 
evaluation.
• One commercial diagnostic manufacturer has received an EUA for a 
serologic test for Zika virus infection
• Three independent laboratories are conducting performance evaluation of three 
manufacturers’ Zika serological assays, as another commercial MAC-ELISA option.
• Three commercial laboratories (Quest, LabCorp, and Mayo) have been 
qualified to use CDC Zika MAC-ELISA.
Nucleic Acid-based EUAs
Test Specimen Type EUA Issuance
CDC Trioplex Real-time RT-PCR 
Serum, CSF, Whole Blood, Urine, and Amniotic 
Fluid 
March 17, 2016
Zika Virus RNA Qualitative Real-Time RT-PCR 
Focus Diagnostics, Inc.(Quest)
Serum April 28, 2016
RealStar Zika Virus RT-PCR Kit U.S.
Altona Diagnostics GmbH
Serum or Urine May 13, 2016
Hologic Aptima Zika Virus assay 
(transcription-mediated amplification test)
Serum, Plasma, Urine June 17, 2016
Viracor-IBT Laboratories, Inc.'s Zika Virus Real-time RT-PCR Test Serum, Plasma, Urine July 19, 2016
VERSANT® Zika RNA 1.0 Assay (kPCR) Kit 
Siemens Healthcare Diagnostics Inc.
Serum, Plasma, Urine July 29, 2016
xMAP® MultiFLEX™ Zika RNA Assay
Luminex Corporation 
Serum, Plasma, Urine August 4, 2016
LightMix® Zika rRT-PCR Test
Roche Molecular Systems, Inc.
Serum or Plasma August 26, 2016
Sentosa® SA ZIKV RT-PCR Test
Vela Diagnostics USA, Inc.
Serum, Plasma, Urine September 23, 2016
Zika Virus Detection by RT-PCR Test 
ARUP Laboratories
Serum, Plasma, Urine September 28, 2016
Abbott RealTime Zika Assay
Abbott Molecular Inc.
Serum, Plasma, Urine November 21, 2016
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika
Zika MAC-ELISA EUAs
Test Specimen Type EUA Issuance
CDC Zika MAC-ELISA Serum, CSF June 29, 2016
ZIKV Detect™ IgM Capture ELISA 
(InBios, USA)
Serum August 17, 2016
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika
Additional Capacity for Zika Diagnostic Testing
In addition, CDC is
• Meeting with states with a high risk of local transmission
• Developing capacity to meet potential testing demand
• Providing reagents to support testing for the Zika virus through the 
International Reagent Resource (IRR) program 
• Including support for approved domestic and US territories 
(including Puerto Rico)
Summary
• Updated laboratory guidance released in November 2016
• Expands testing parameters, such as whole blood (CDC Trioplex NAT)
• Recommend collect whole blood (improved sensitivity) 
• Large volume (1.0 mL) extraction is preferred (serum, urine, CSF, 
amniotic fluid to improve sensitivity)
• Must still collect serum for serologic assays 
• CDC-developed and several commercial assays authorized under FDA EUA 
for Zika virus testing
Diagnostic Testing for Zika Virus 
in Clinical Laboratories
Matthew J. Binnicker, Ph.D., D(ABMM)
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Controlling Zika – A TEAM Effort
• Success will depend on careful coordination
and cooperation among providers, public 
health, and clinical laboratories.
• Involvement of local/private labs and 
reference laboratories is essential:
– Closest to the patient
– Reduce burden of testing on public health labs
Diagnostic Assays for Zika Virus
• Currently require Emergency Use Authorization 
(EUA) from the FDA prior to use.
• CDC assays first to receive EUA
– TrioPlex rRT-PCR* – molecular test for detection of 
Zika, dengue and chikungunya viruses from:
• Serum (preferred)
• Whole blood
• CSF
– MAC-ELISA** – serology for detection of IgM
*Available in CDC-designated public health labs
**Available in CDC-designated public health and reference labs
• Urine
• Amniotic fluid
Zika testing only
Diagnostic Assays for Zika Virus
• Several commercial assays are now available:
Laboratory/Company Method Sample type(s)
Focus/Quest Diagnostics Real-time RT-PCR Serum, urine
altona Diagnostics Real-time RT-PCR Serum, urine
Hologic TMA Plasma, serum, urine
Viracor-IBT Real-time RT-PCR Plasma, serum, urine
Siemens Real-time RT-PCR Plasma, serum, urine
Luminex Real-time RT-PCR Plasma, serum, urine
Roche Real-time RT-PCR Plasma, serum
InBios IgM Capture ELISA Serum
How should these tests be used?
Case #1
• A 27 year-old female returns from vacation in 
Jamaica. Seven days after arriving home, the 
patient takes a pregnancy test, which is 
positive. The patient is asymptomatic.
• Is Zika testing recommended, and if so, what 
testing should be performed?
Case #1 – Testing recommended
<14 days after return from travel 
or exposure?
>14 days (2-12 weeks) after 
return from travel or exposure?
Case #1 – Testing recommended
<14 days after return from travel 
or exposure?
>14 days (2-12 weeks) after 
return from travel or exposure?
Test serum (and urine/whole 
blood*) by RT-PCR for Zika only
Test serum by IgM serology
Any POSITIVE
Zika infection
All NEGATIVE
Test serum by IgM serology 2-12 
weeks after return from travel
*Optional; must be accompanied by paired serum
Case #2
• A 45 year-old male from Honduras visits his 
family in Texas. He was well during his first 7 
days in the U.S., but has experienced an 
intermittent low grade fever, rash and mild 
joint pain over the past 2.5 weeks.
• Is Zika testing indicated?
Case #2 – Testing indicated
<14 days following 
symptom onset?
>14 days following 
symptom onset?
Case #2 – Testing indicated
<14 days following 
symptom onset?
>14 days following 
symptom onset?
Test serum (and urine/whole 
blood*) by RT-PCR for Zika, ChikV
and Dengue
Test serum by Zika IgM serology 
(also ChikV† and Dengue IgM)
Zika IgM POSITIVE
ChikV NEG; Dengue EQUIVOCAL
All NEGATIVE
Serum tested by PRNT‡ at CDC 
or CDC-designated lab *Optional – must be accompanied by serum
†ChikV – chikungunya virus
‡PRNT – plaque reduction neutralization test
Case #3
• A 57 year-old female from Des Moines, IA visits 
Haiti as part of a church mission trip. Two days 
after returning home, she contacts her primary 
care provider and requests testing for Zika. The 
patient is asymptomatic.
• Is Zika testing recommended?
Case #3
• “Diagnostic” testing is not recommended in 
asymptomatic, non-pregnant individuals.
• Caveat: Blood donors (Organ/tissue donors**)
On August 26, 2016, the U.S. FDA 
recommended that all donated blood be 
screened for Zika virus
• Currently, two screening tests available:
– Nucleic acid amplification tests (Roche and Hologic)
**No definitive guidance; however, may be 
screened. Recommended screening test (PCR 
vs. serology) unclear.
Case #4
• A 29 year-old female with laboratory 
confirmed Zika virus infection delivers her first 
child. Clinical exam of the infant reveals no 
evidence of abnormalities.
• Is Zika testing of the infant recommended?
Case #4 – Testing indicated
• Lab testing is recommended for:
– Infants born to mothers with lab evidence of Zika
– Infants with findings suggestive of congenital Zika 
AND a maternal epidemiologic link (regardless of 
maternal test results)
• Initial testing of infant should include:
– rRT-PCR of serum and urine (whole blood/CSF optional)
– Zika virus IgM on serum
Case #4 – Interpretation
• Interpretation of results of lab testing in cases of 
possible congenital Zika virus infection:
Zika rRT-PCR Zika IgM Interpretation
Positive* Positive or Negative Confirmed congenital Zika infection
Negative Positive Probable congenital Zika infection
Negative Negative Negative for congenital Zika infection
*Infant serum, urine or cerebrospinal fluid
Case #4 – Interpretation
• Interpretation of results of lab testing in cases of 
possible congenital Zika virus infection:
Zika rRT-PCR Zika IgM Interpretation
Positive* Positive or Negative Confirmed congenital Zika infection
Negative Positive Probable congenital Zika infection
Negative Negative Negative for congenital Zika infection
*Infant serum, urine or cerebrospinal fluid
Case #4 – Interpretation
• Interpretation of results of lab testing in cases of 
possible congenital Zika virus infection:
Zika rRT-PCR Zika IgM Interpretation
Positive* Positive or Negative Confirmed congenital Zika infection
Negative Positive Probable congenital Zika infection
Negative Negative Negative for congenital Zika infection
*Infant serum, urine or cerebrospinal fluid
Summary
• Zika virus poses a significant challenge to 
public health and clinical laboratories.
• Coordinated effort is needed to identify cases 
and control the outbreak.
• Evolving process – new data will continue to 
guide diagnostic algorithms.
Analysis. Answers. Action. www.aphl.org
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Parallels to the Ebola Response
Ebola
• Not much known 
about virus
• Confusion 
surrounding testing
• Confusion about 
specimen shipment
• Many different health 
care professionals 
involved
Zika
• Not much known 
about virus
• Confusion 
surrounding testing
• Confusion about 
specimen shipment
• Many different health 
care professionals 
involved
Analysis. Answers. Action. www.aphl.org
Where to Get Testing
• Public Health Laboratories
– Check city, county, or state health 
department websites for testing specifics
• Commercial and private laboratories 
– See current assay availability at FDA Medical 
Device EUA website
– Check individual lab websites for which 
tests are offered
Analysis. Answers. Action. www.aphl.org
Specimen Submission
• Specimen handling requirements 
– Check recommendations for each lab
• Specimens approved for testing based 
on patient signs and symptoms and 
travel history
– Extra information needed for determining if 
patient meets testing criteria
– This information is also required for 
additional testing at CDC 
Analysis. Answers. Action. www.aphl.org
Where are my Results?
Reverse Transcriptase – Polymerase Chain 
Reaction (RT-PCR)
• Serum is preferred specimen
• Trioplex assay - urine, whole blood, CSF can 
be tested when submitted with paired serum
• Positive results are considered conclusive; no 
other testing required
• Results available approximately 2 -3 days after 
specimen arrives in the laboratory
Analysis. Answers. Action. www.aphl.org
Where are my Results?
IgM Antibody Capture enzyme-linked
Immunosorbent Assay (MAC-ELISA)
• Serum is only suitable specimen
• Results available approximately 3 – 4 days 
after arrival in the laboratory
• Plaque-reduction neutralization test (PRNT) 
used to confirm positive or equivocal results
• Dengue and Chikungunya serology are 
recommended depending on where infected
Analysis. Answers. Action. www.aphl.org
Where are my Results?
Plaque-reduction neutralization test (PRNT)
• Serum is the preferred specimen
• Only CDC and a few CDC approved 
laboratories can perform this test
• Results should be interpreted in conjunction 
with the serology test results
• Test measures specific antibodies to Zika and 
other flaviviruses
• Test depends on virus growth which may be at 
least one week or more
Analysis. Answers. Action. www.aphl.org
Working With Partners
Commercial and Private Lab Coordination 
• Private labs have contacted us regarding their 
implementation of RT-PCR testing and offered 
their testing capacity if needed
• Commercial labs are working with PHLs to 
provide surge capacity testing as part of a 
large scale investigation
• In some areas these labs can provide needed 
local capacity for specimen collection
Analysis. Answers. Action. www.aphl.org
Working With Partners
Military and Federal Lab Coordination
• Many military labs have implemented Zika RT-
PCR and IgM testing and have indicated they 
would be available to provide surge testing
• Federal (CDC) labs provide PRNT testing for 
PHLs and other commercial labs; also have 
additional surge capacity to support local 
transmission investigations
Analysis. Answers. Action. www.aphl.org
Education and Outreach
Health Department Activities
• Media campaigns
• Webinars with health care providers
– State Medical Association
– State Pediatric Society
– State Ob/Gyn Association
• Use of WIC sites for distribution of pamphlets 
and posting of educational materials
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
http://emergency.cdc.gov/coca/calls/2016/callinfo_120116.asp
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Upcoming COCA Call
registration is not required
Risk Mitigation Strategies to Reduce Opioid Overdoses 
 Date: Tuesday, December 6, 2016
 Time: 2:00 – 3:00 pm (Eastern)
 Presenters:
 Deborah Dowell, MD, MPH—CDC
 Jane C Ballantyne, MD, FRCA—University of Washington
 Joseph O. Merrill MD, MPH—University of Washington
http://emergency.cdc.gov/coca
Upcoming COCA Call
registration is not required
Gearing up for the Travel Season: How Clinicians can 
Ensure Their Patients are Packed with Knowledge on 
Zika Prevention
 Date: Thursday, December 8, 2016
 Time: 2:00 – 3:00 pm (Eastern)
 Presenters:
 Mary Tanner, MD, FAAP—CDC Zika Pregnancy and Birth 
Defects Task Force
 Allison Taylor Walker PhD, MPH—CDC Zika Travelers’ 
Health Branch
http://emergency.cdc.gov/coca
Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
AAVSB/RACE) for COCA Calls are issued online through the CDC Training 
& Continuing Education Online system (http://www.cdc.gov/TCEOnline/).
Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by December 
31, 2016 with the course code WC2286. Those who will participate in the 
on demand activity and wish to receive continuing education should 
complete the online evaluation between December 31, 2016 and November 
30, 2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
Join the COCA Mailing 
List
Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and 
response conferences and 
training opportunities
http://emergency.cdc.gov/coca 
Join Us on 
Facebook
CDC Facebook page 
for clinicians! “Like” 
our page today to 
learn about upcoming 
COCA Calls, CDC 
guidance and 
recommendations, and 
other health alerts
CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
